|
|
|
|
|
|
Sponsored by: |
International Extranodal Lymphoma Study Group (IELSG) |
Information provided by: | International Extranodal Lymphoma Study Group (IELSG) |
ClinicalTrials.gov Identifier: | NCT00210340 |
The purpose of this study is to define the safety profile of rituximab given intrathecally in lymphomatous meningitis related to CD20+ non-Hodgkin’s lymphomas.
Condition | Intervention | Phase |
Lymphoma, B Cell |
Drug: intrathecal rituximab |
Phase I |
MedlinePlus related topics: | Lymphoma Meningitis |
ChemIDplus related topics: | Rituximab |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis |
Estimated Enrollment: | 9 |
Study Start Date: | June 2004 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Contact: Cristina Morinini | +41 91 8119040 | ielsg@ticino.com |
Switzerland | |||||
Oncology Institute of Southern Switzerland (IOSI) | Recruiting | ||||
Bellinzona, Switzerland, 6500 | |||||
Contact: Cristina Morinini +41 91 8119040 ielsg@ticino.com |
International Extranodal Lymphoma Study Group (IELSG) |
Study Chair: | Annarita Conconi, MD | International Extranodal Lymphoma Study Group/Hematology Division. University Amedeo Avogadro. Novara |
Study Chair: | Andres JM Ferreri, MD | Radiochemotherapy San Raffaele Hospital. Milan |
Click here for more information about this study: phase I study of intrathecal rituximab in patients with lymphomatous meningitis 
  |
Study ID Numbers: | IELSG24 |
First Received: | September 13, 2005 |
Last Updated: | September 13, 2005 |
ClinicalTrials.gov Identifier: | NCT00210340 |
Health Authority: | Switzerland: Swissmedic |
|
|
|
|